Report on malignancies in the German juvenile idiopathic arthritis registry

Rheumatology

Volumn 50, Issue 1, 2011, Pages 230-236

  Horneff, Gerd ^a   Foeldvari, Ivan ^b   Minden, Kirsten ^c   Moebius, Dagmar ^d   Hospach, Toni ^e  

^a Asklepios Clinic Sankt Augustin   (Germany)

^b Hamburger Zentrum fur Kinder und Jugendrheumatologie   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Carl Thiem Hospital   (Germany)

^e Pediatric Rheumatology   (Germany)

Author keywords

Anti TNF ; Biologics; Childhood; Juvenile idiopathic arthritis; Lymphoma; Malignancy; MTX; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DICLOFENAC; ETANERCEPT; IMMUNOGLOBULIN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; PREDNISOLONE; PREDNISONE; THYROXINE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR INHIBITOR; VALDECOXIB;

ADOLESCENT; ADULTHOOD; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CASE STUDY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DISEASE REGISTRY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GERMANY; HODGKIN DISEASE; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; LYMPH NODE BIOPSY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT INFORMATION; PREMEDICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SURGICAL TECHNIQUE; THYROID CARCINOMA; TREATMENT PLANNING; UTERINE CERVIX DYSPLASIA; YOLK SAC CARCINOMA;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; INFANT; LYMPHOMA; MALE; METHOTREXATE; NEOPLASMS; REGISTRIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951691845     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq361     Document Type: Article

References (46)

1. Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
2. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
3. Bernatsky S, Rosenberg A, Oen KG et al. Malignancy in juvenile idiopathic arthritis. Arthritis Rheum 2009;60(Suppl. 10):Abstract 250.
4. Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009; 48:257-67.
5. Falcini F, Bardare M, Cimaz R, Lippi A, Corona F. Arthritis as a presenting feature of non-Hodgkin's lymphoma. Arch Dis Child 1998;78:367-70.
6. Flatø B, Aasland A, Vinje O, Førre O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998;25: 366-75.
7. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006;65:617-22.
8. Robert Koch Institute and Society of the Epidemiological Cancer Registry in Germany e. V., eds. Cancer in Germany 2003-2004: frequencies and trends, 6th Edition. Berlin, 2008. http://www.ekr.med.uni-erlangen.de/GEKID/Doc/kid2008_english.pdf.
9. Giannini EH, Brewer EJ, Kuzmina N et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
10. Giannini EH, Ilowite NT, Lovell DJ et al. Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
11. Hellgren K, Iliadou A, Rosenquist R et al. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis 2010;69:654-9.
12. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA registry. Ann Rheum Dis 2009;68: 519-25.
13. Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2004;63:638-44.
14. Horneff G. [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Worlitz meeting 2004 for the German Society of Pediatric and Adolescent Rheumatology. Z Rheumatol 2006;65:152-8.
15. Horneff G. Medical treatment of juvenile idiopathic arthritis. Med Monatsschr Pharm 2008;31:326-36.
16. Hospach T, Haas JP, Huppertz HI et al. [Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration regarding cases of malignancy in anti-TNF-treated patients]. Z Rheumatol 2009;68:162-4.
17. Imundo L. Hodgkin's lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: supplemental case report. J Rheumatol 2008;35:1681.
18. Kaatsch P. Jahresbericht Kinderkrebsregister 2008. http://www.kinderkrebsregister.de (25 October 2010, date last accessed).
19. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10: 3049-60.
20. Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986;13:118-23.
21. Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immuno-suppressive agents. Crit Rev Oncol/Hematol 2005;56: 169-78.
22. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
23. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54: 1987-94.
24. Lovell DJ, Ruperto N, Goodman S et al. Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
25. Lovell DJ, Reiff A, Ilowite NT et al. Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58: 1496-504.
26. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009;48:386-8.
27. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
28. Minden K, Niewerth M, Listing J et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392-401.
29. Minden K, Niewerth M, Listing J, Biedermann T, Schöntube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:836-42.
30. Navarro JT, Ribera JM, Mate JL et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003; 44:531-3.
31. Petty RE. Prognosis in children with rheumatic diseases: justification for consideration of new therapies. Rheumatology 1999;38:739-42.
32. Pontikaki I, Gerloni V, Gattinara M et al. Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo 2006;58:31-8.
33. Prince FH, Twilt M, Ten Cate R et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
34. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
35. Ruperto N, Lovell DJ, Cuttica R et al. Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group: a randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
36. Ruperto N, Ravelli A, Castell E et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006;5:599-605.
37. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996;334:1238-48.
38. Silverman E, Mouy R, Spiegel L et al. Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66.
39. Thomas E, Brewster DH, Black RJ, MacFarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
40. Trapani S, Grisolia F, Simonini G, Calabri GB, Falcini F. Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum 2000;29: 348-59.
41. US Food and Drug Administration. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). Silver Spring, MD, USA: FDA, 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070725.htm (6 April 2008, date last accessed).
42. US Food and Drug Administration. Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) Silver Spring, MD, USA: FDA, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients-andProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm (6 April 2008, date last accessed).
43. US Food and Drug Administration. Questions and Answers - TNF Blockers 8/25/2009. Silver Spring, MD, USA: FDA, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm180694.htm (6 April 2008, date last accessed).
44. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
45. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet 1998;351:969-73.
46. Yildirim-Toruner C, Kimura Y, Rabinovich E. Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J Rheumatol 2008;35:1680-1.